Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28662518 | 0.99 | GLP1R (0.84) | GLP1R | |
| SCHEMBL29942605 | 0.99 | GLP1R (0.84) | GLP1R | |
| SCHEMBL29801807 | 0.99 | GLP1R (0.84) | GLP1R | |
| SCHEMBL29431871 | 0.99 | GLP1R (0.84) | GLP1R | |
| SCHEMBL31099271 | 0.99 | GLP1R (0.84) | GLP1R | |
| SCHEMBL30498859 | 0.99 | GLP1R (0.82) | GLP1R | |
| SCHEMBL30498862 | 0.99 | GLP1R (0.82) | GLP1R | |
| SCHEMBL30498860 | 0.99 | GLP1R (0.82) | GLP1R | |
| SCHEMBL30498858 | 0.99 | GLP1R (0.82) | GLP1R | |
| SCHEMBL30498861 | 0.99 | GLP1R (0.82) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4968 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137648-A1 | COMPOSITIONS COMPRISING SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS IN COMBINATION WITH WEIGHT LOSS DRUGS AND USES THEREOF FOR INCREMENTAL WEIGHT LOSS AND MANAGEMENT OF ADVERSE SIDE EFFECTS OF WEIGHT LOSS DRUGS ON BODY COMPOSITION | VERU INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099117-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL | MERCK PATENT GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4739301-A1 | COMPOSITIONS CONTAINING, AND COMBINATION THERAPIES USING BEMPEDOIC ACID AND A GLP-1 RECEPTOR AGONIST | Esperion Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4736844-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 ANALOG AND AN INORGANIC MESOPOROUS MATERIAL | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090182-A1 | GLP-1 RECEPTOR AGONIST AND URSOLIC ACID COMBINATIONS AND USE THEREOF FOR INCREASING WEIGHT LOSS WHILE IMPROVING MUSCLE MASS AND STRENGTH | EMMYON, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087536-A1 | METHODS OF USING HOMOTAURINE AND ANALOGS THEREOF FOR THE TREATMENT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST INDUCED GASTROINTESTINAL SIDE EFFECTS | UNIVERSITY OF TARTU (EE) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090181-A1 | GLP-1 RECEPTOR AGONIST COMBINATIONS AND USE THEREOF FOR INCREASING WEIGHT LOSS WHILE IMPROVING MUSCLE MASS AND STRENGTH | EMMYON, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731243-A2 | IN SITU THERAPEUTIC PRODUCTION: METHODS AND COMPOSITIONS | William Marsh Rice University (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4733314-A1 | NOVEL BISPECIFIC FUSION PROTEIN AND USE THEREOF | Slbigen Inc. (KR) | 2026-04-29 | — | — | EP | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2022042691-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| CN-114081867-A | Method for improving drug loading capacity of microspheres | 中国药科大学 | 2022-02-25 | — | — | CN | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| US-11253686-B2 | Swallowable drug delivery device and methods of drug delivery | RANI THERAPEUTICS, LLC (US) | 2022-02-22 | — | — | US | claimed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3952855-A1 | COMBINATION THERAPY COMPRISING COMPOUNDS OF FORMULA (I) AND GLP-1 RECEPTOR AGONISTS | Genfit (FR) | 2022-02-16 | — | — | EP | claimed |
| EP-3952847-A1 | IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS | Foundry Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022029231-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-10 | — | — | WO | claimed |
| WO-2022028572-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-02-10 | — | — | WO | claimed |